Conversely, responders to ICB therapies exhibit increased antigen-presenting cell populations, aligning with studies that associate MHC class II (HLA-DR) molecule expression in melanomas with higher densities of CD8+ tumor-infiltrating lymphocytes (TILs) and favorable anti-PD-1 therapy responses (67, 68). The gene discussed is CD8A; the disease is melanoma.